Earnings summaries and quarterly performance for Upstream Bio.
Executive leadership at Upstream Bio.
Board of directors at Upstream Bio.
Research analysts covering Upstream Bio.
Recent press releases and 8-K filings for UPB.
Upstream Bio Provides Update on Verekitug Clinical Development and Market Opportunity
UPB
Product Launch
New Projects/Investments
- Upstream Bio's CEO, Rand Sutherland, presented on verekitug, a TSLP receptor-targeting drug, highlighting its differentiated profile with 100% receptor occupancy for up to 24 weeks and potential for every 12-week or 24-week dosing.
- The company reported positive Phase 2 results for verekitug in chronic rhinosinusitis with nasal polyps (CRS with NP), showing a 1.8-point reduction in endoscopic nasal polyp score and a 76% reduction in the need for surgery or steroids.
- The severe asthma study (Valiant) data readout is anticipated this quarter (Q1 2026), with the trial powered to detect a 50% reduction in asthma exacerbations.
- Upstream Bio is targeting multi-billion dollar markets in severe asthma, CRS with NP, and COPD, aiming for differentiated efficacy and broad patient populations.
3 days ago
Upstream Bio Highlights Positive Phase 2 Data for Virecetug in CRS with NP and Upcoming Severe Asthma Readout
UPB
New Projects/Investments
- Upstream Bio, a clinical-stage company, is developing Virecetug, a drug targeting the TSLP receptor for severe respiratory diseases, including chronic rhinosinusitis with nasal polyps (CRS with NP), severe asthma, and chronic obstructive pulmonary disease (COPD).
- Recent Phase 2 trial data for CRS with NP showed a statistically and clinically significant reduction of 1.8 points in endoscopic nasal polyp score and a 76% reduction in the need for surgery or steroids.
- The company expects to read out Phase 2 data for severe asthma by the end of Q1 2026. This trial is powered to detect a 50% or greater reduction in annualized asthma exacerbation rates.
- Virecetug demonstrates unique pharmacology, including 100% receptor occupancy for up to 24 weeks after the last dose, enabling infrequent dosing (two or four times per year), and has maintained a clean safety profile across studies.
3 days ago
Upstream Bio Reports Positive Phase 2 CRSwNP Results and Provides Pipeline Update
UPB
Product Launch
New Projects/Investments
Guidance Update
- Upstream Bio, a clinical-stage immunology company, is developing vereitug, the only known clinical-stage antagonist of the TSLP receptor, for severe respiratory diseases.
- The VIBRANT Phase 2 trial for chronic rhinosinusitis with nasal polyps (CRSwNP) reported positive top-line results in September 2025, demonstrating a -1.8 reduction in nasal polyp score (NPS) (p<0.0001) and a 76% reduction in the need for surgery/steroids with 12-week dosing.
- Upcoming catalysts include top-line results for the VALIANT Phase 2 trial in severe asthma, expected in Q1 2026, while the VENTURE Phase 2 trial in COPD is actively enrolling.
- Verekitug has shown high potency in asthma patients, with a modeled effect on FENO that is ~1.5 times greater than tezepelumab and >300-fold lower EC50/EC90, enabling potential extended dosing intervals of up to 24 weeks.
- The company's existing capital is expected to fund planned operations through 2027, addressing a global biologics market for asthma and COPD projected to exceed $35 billion by mid-2030s.
3 days ago
Upstream Bio Highlights Positive Phase 2 Data for Virecetug in CRS with NP and Upcoming Asthma Data
UPB
New Projects/Investments
- Upstream Bio, a clinical-stage company, is developing Virecetug, a drug targeting the TSLP receptor for severe respiratory diseases, with potential for infrequent dosing (two or four times per year).
- Recent Phase 2 data for chronic rhinosinusitis with nasal polyps (CRS with NP) demonstrated a significant and statistically significant reduction in endoscopic nasal polyp score of 1.8 points and a 76% reduction in the need for surgery or steroids, alongside an unblemished safety profile.
- The Phase 2 severe asthma trial (Valiant) is expected to report data in Q1 2026, and is powered to detect a 50% or greater reduction in annualized asthma exacerbation rates.
- A Phase 2 trial in chronic obstructive pulmonary disease (COPD) has also recently commenced enrollment.
- The company aims for Virecetug to offer a differentiated profile with best-in-class efficacy and less frequent dosing across a broad patient population in multi-billion dollar markets.
3 days ago
Upstream Bio Highlights Positive Phase II Data for Verekitug and Upcoming Asthma Results
UPB
Product Launch
New Projects/Investments
- Upstream Bio (UPB) transitioned to a mid-stage clinical development company in 2025, marked by the release of positive Phase II placebo-controlled data for verekitug in chronic rhinosinusitis with nasal polyps (CRS with NP).
- The Phase II CRS with NP data for verekitug demonstrated strong efficacy with every 12-week dosing, positioning it as potentially best-in-class.
- Verekitug is a monoclonal antibody that uniquely targets the TSLP receptor, offering the potential for extended dosing intervals (up to 24 weeks after the last dose) and enhanced potency compared to ligand-targeting therapies.
- The company expects to release severe asthma data in the first quarter of 2026, aiming for approximately a 50% reduction in annualized asthma exacerbation rate with Q12 week dosing.
- Upstream Bio is also progressing a Phase II COPD trial, which began dosing patients over the summer, with the goal of demonstrating efficacy across a broad patient population.
Dec 4, 2025, 3:25 PM
Upstream Bio discusses Virectib clinical trial progress and future plans
UPB
New Projects/Investments
- Upstream Bio's biggest accomplishment in 2025 was transitioning to a mid-stage development company, highlighted by positive Phase 2 placebo-controlled data for Virectib in chronic rhinosinusitis with nasal polyps (CRS with NP).
- Virectib is a monoclonal antibody targeting the TSLP receptor, distinguishing it from competitors like Tezepelamab, and allows for extended every 12-week dosing.
- The Phase 2 Vibrant study in CRS with NP showed a 1.8-point reduction in the endoscopic nasal polyp score, significant reductions in nasal congestion, and improved sinusitis, all delivered at Q12 week dosing.
- Upstream Bio anticipates releasing severe asthma data (Valiant study) in Q1 2026, aiming for approximately a 50% reduction in annualized asthma exacerbation rate with Q12 week dosing.
- The company plans to wait for the asthma data before initiating Phase 3 trials for both CRS with NP and severe asthma, with the goal of potentially launching in both indications around the same time. A Phase 2 COPD trial is also underway, with data expected further out.
Dec 4, 2025, 3:25 PM
Upstream Bio Discusses Virectib Clinical Development and Upcoming Asthma Data
UPB
New Projects/Investments
Guidance Update
- Upstream Bio has transitioned to a mid-stage clinical development company, reporting positive Phase 2 placebo-controlled data for Virectib in chronic rhinosinusitis with nasal polyps (CRS with NP), demonstrating strong efficacy with every 12-week dosing.
- The company expects to release data for Virectib in severe asthma (Valiant study) in the first quarter of 2026, with the positive CRS data increasing confidence for this upcoming readout.
- Virectib differentiates itself by targeting the TSLP receptor, which contributes to its high potency and potential for extended dosing intervals (Q12 week, with potential for Q24 week).
- Following the asthma data, Upstream Bio intends to initiate Phase 3 development for both CRS with NP and severe asthma, aiming for a potential simultaneous launch.
Dec 4, 2025, 3:25 PM
Upstream Bio Confirms Q1 2026 Verekitug Asthma Data Readout and Outlines Phase 3 Strategy
UPB
Guidance Update
New Projects/Investments
- Upstream Bio anticipates Verekitug asthma data readout in Q1 2026, confirming previous guidance, following enrollment completion on June 9, 2025, for its 24-week study.
- The company aims for a 50% reduction in exacerbations on a placebo-adjusted basis for Verekitug, with potential for a highly differentiated profile due to its extended dosing intervals (quarterly or every six months) and several hundred-fold greater potency compared to Tezepelamab.
- Upstream Bio plans to leverage data from both severe asthma and chronic rhinosinusitis with nasal polyps (CRS with NP) trials for robust dose selection for Phase 3, with the ambition to prosecute both programs approximately simultaneously, ideally with a single dose regimen for both diseases.
Dec 2, 2025, 9:30 PM
Upstream Bio Provides Update on VALIANT Asthma Data and Phase 3 Development Plans
UPB
Guidance Update
New Projects/Investments
- Upstream Bio (UPB) anticipates the release of VALIANT asthma data in Q1 2026, following the completion of enrollment on June 9th and a 24-week study period.
- The company is targeting a 50% reduction in exacerbations for its verekitug treatment in severe asthma, aiming for a highly differentiated profile with quarterly (Q12 weeks) or every six months (Q24 weeks) dosing intervals.
- Verekitug demonstrates significantly higher potency than tezepelamab, which is expected to support extended dosing and broad patient eligibility, positioning it competitively against existing biologics.
- Upstream Bio plans to leverage data from both severe asthma and chronic rhinosinusitis with nasal polyps trials to select a single dose regimen for Phase 3, with the ambition to simultaneously advance both programs.
Dec 2, 2025, 9:30 PM
Upstream Bio Provides Update on Verekitug Asthma Program and Market Strategy
UPB
Guidance Update
New Projects/Investments
- Upstream Bio (UPB) anticipates the Verekitug asthma data readout in Q1 2026, with enrollment completion on June 9th and a 24-week study period aligning with a February/March timeline.
- The company expects a 50% reduction in exacerbations on a placebo-adjusted basis for Verekitug, which would represent a highly differentiated profile if achieved at quarterly or every six months dosing intervals.
- Verekitug has demonstrated several hundred-fold greater potency than Tezepelamab in the clinic, enabling potential extended dosing intervals of every 12 weeks or every 24 weeks.
- UPB plans to leverage data from both severe asthma and chronic rhinosinusitis with nasal polyps (CRS with NP) trials for robust Phase 3 dose selection, with the ambition to initiate both programs approximately simultaneously.
- The company sees significant market opportunity in asthma, where biologics currently have less than 10% penetration of eligible patients, believing a differentiated agent like Verekitug could drive further market growth.
Dec 2, 2025, 9:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more